Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J DeAngelo

Showing results (71-80 of 320) with videos related to

Pageof 32
Sort By:
Current Medical Research and Opinion|October 31, 2014
One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparisonJames E Signorovitch, Keith A Betts, William M Reichmann, et al.
Journal of Thrombosis and Haemostasis : JTH|January 31, 2020
The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTHJeffrey I Zwicker, Tzu-Fei Wang, Daniel J DeAngelo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2008
Recurrent acute promyelocytic leukemia presenting as a sacral nerve root massSantosh Kesari, Jan Drappatz, Serra Akar, et al.
Blood Cancer Journal|December 20, 2023
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemiaAndrew Hantel, Colin Cernik, Hajime Uno, et al.
The Oncologist|August 12, 2025
Barriers and Facilitators to Representative Acute Leukemia Trial Participation at National Cancer Institute-Designated Comprehensive Cancer CentersAndrew Hantel, Eric C Blackstone, Anna C Revette, et al.
Therapeutic Advances in Hematology|January 3, 2017
Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinibSikander Ailawadhi, Luke P Akard, Carole B Miller, et al.
Seminars in Oncology|May 3, 2008
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemiaFrancis J Giles, Daniel J DeAngelo, Michele Baccarani, et al.
Plos One|October 7, 2014
A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemiaAaron D Schimmer, Azra Raza, Thomas H Carter, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 28, 2006
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndromeEdwin P Alyea, Haesook T Kim, Vincent Ho, et al.
British Journal of Haematology|March 9, 2017
Self-reported sleep disturbance and survival in myelodysplastic syndromesMarlise R Luskin, Angel M Cronin, Robert L Owens, et al.
Pageof 32

Showing results (71-80 of 320) with videos related to

Sort By:
Pageof 32
Current Medical Research and Opinion|October 31, 2014
One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparisonJames E Signorovitch, Keith A Betts, William M Reichmann, et al.
Journal of Thrombosis and Haemostasis : JTH|January 31, 2020
The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTHJeffrey I Zwicker, Tzu-Fei Wang, Daniel J DeAngelo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2008
Recurrent acute promyelocytic leukemia presenting as a sacral nerve root massSantosh Kesari, Jan Drappatz, Serra Akar, et al.
Blood Cancer Journal|December 20, 2023
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemiaAndrew Hantel, Colin Cernik, Hajime Uno, et al.
The Oncologist|August 12, 2025
Barriers and Facilitators to Representative Acute Leukemia Trial Participation at National Cancer Institute-Designated Comprehensive Cancer CentersAndrew Hantel, Eric C Blackstone, Anna C Revette, et al.
Therapeutic Advances in Hematology|January 3, 2017
Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinibSikander Ailawadhi, Luke P Akard, Carole B Miller, et al.
Seminars in Oncology|May 3, 2008
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemiaFrancis J Giles, Daniel J DeAngelo, Michele Baccarani, et al.
Plos One|October 7, 2014
A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemiaAaron D Schimmer, Azra Raza, Thomas H Carter, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 28, 2006
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndromeEdwin P Alyea, Haesook T Kim, Vincent Ho, et al.
British Journal of Haematology|March 9, 2017
Self-reported sleep disturbance and survival in myelodysplastic syndromesMarlise R Luskin, Angel M Cronin, Robert L Owens, et al.
Pageof 32